A new review from the Icahn School of Medicine at Mount Sinai and the Hospital Clínic de Barcelona provides one of the clearest roadmaps to date for understanding and treating liver cancer, one of the deadliest cancers worldwide. Published in Cell, the study, “Hallmarks of Liver Cancer: Therapeutic Implications”, applies the widely used “Hallmarks of Cancer” framework to liver tumors, linking the biology of the disease to treatment strategies, including immunotherapy and precision medicine approaches, particularly in the approximately 45% of bile duct cancers that harbor targetable mutations.

The study was led by Josep M. Llovet, MD, Ph.D., Professor of Medicine at the Icahn School of Medicine (Liver Diseases) at Mount Sinai and Director of the Liver Cancer Program at the Mount Sinai Tisch Cancer Center; and Daniela Sia, Ph.D., Associate Professor of Medicine (Liver Diseases) at the Icahn School of Medicine.

Marking the 25th anniversary of the groundbreaking “Hallmarks of Cancer” framework introduced by Douglas Hanahan, Ph.D. (Swiss Institute for Experimental Cancer Research), and Robert A. Weinberg, Ph.D. (Massachusetts Institute of Technology), the Mount Sinai-led team applies this influential model specifically to primary liver cancer, offering new insights into disease biology and treatment strategies.